Novavax Appoints Dr. Robert Walker as EVP of R&D to Drive Pipeline Growth
Novavax elevated Dr. Robert Walker to Executive Vice President and Head of R&D, leveraging his 30 years in drug and vaccine development to lead preclinical and clinical programs. He will oversee Matrix adjuvant innovations and data generation efforts to drive strategic partnerships and accelerate advancement of the company’s pipeline assets.
1. Executive Appointment
Novavax has appointed Dr. Robert Walker as Executive Vice President and Head of Research & Development, reporting to CEO John C. Jacobs. He succeeds Dr. Ruxandra Draghia-Akli and will strengthen leadership across preclinical and clinical functions.
2. Extensive Experience
Dr. Walker brings over 30 years of drug and vaccine development expertise, including roles as Chief Medical Officer at the Biomedical Advanced Research and Development Authority and as Novavax’s Chief Medical Officer since 2022.
3. Strategic R&D Focus
In his new role, Dr. Walker will oversee preclinical and clinical operations, emphasizing Matrix-M adjuvant innovation, rigorous data generation for regulatory filings, and collaboration to forge strategic partnerships that drive the company’s pipeline into late-stage development.